正在加载视频...

视频加载失败

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic...

42,494 次观看 • 1 年前 •via X (Twitter)

9 条评论

LinnBee🌸 的头像
LinnBee🌸1 年前

Nice. Does this need any immuno suppressants? Stem cell is a very exciting field.

Michael Moraal 的头像
Michael Moraal1 年前

@amsterdamumc @DiabetesNL ik hoop dat VX-264 ook naar Nederland komt na die FDA submission 🙏

john callinan 的头像
john callinan1 年前

@isletbiologylab For the first time a cure in five years may actually be accurate.

L A U R A ... ♥🌼 的头像
L A U R A ... ♥🌼1 年前

This would be so much more heartwarming if it was for ALL T1, not just some. A great effort so far, but can it really be classed as a T1 cure if not all T1s can be cured?

BioBoost 的头像
BioBoost1 年前

Could targeting insulin-degrading enzyme (IDE) hold the key to preventing Type 1 diabetes? A recent study shows that IDE deficiency in mice reduces autoreactive immune cells and insulin-specific immune responses, protecting pancreatic cells from autoimmune destruction and lowering Type 1 diabetes risk. Could IDE be a potential target for autoimmune diabetes therapies?

سعودي ولي الفخر🇸🇦 的头像
سعودي ولي الفخر🇸🇦1 年前

متى نرى هذا العلاج النهائي في الأسواق؟؟

Swati Rights 的头像
Swati Rights1 年前

While it gives a lot of optimism I'm also wondering what impact it will have in terms of side effects that may trigger new autoimmune conditions, affect organs like the kidney, liver and heart, or produce conditions like cancer or bone affliction later Is there any literature ?

Brady Gretch 的头像
Brady Gretch1 年前

@BreakthroughT1D Thank you for sharing this great news with a text and video post!

Rachel Harman 的头像
Rachel Harman1 年前

I would love for my son to be a part of this! He is only 12 and struggling with type one.

相关视频

Today, more than 170 delegates from all 50 states and five countries were in Washington for the 2025 Breakthrough Type 1 Diabetes Children’s Congress. I was proud to chair a Senate Appropriations Committee hearing to welcome the delegates and focus on the importance of federal investment in Type 1 diabetes research. Senator Jeanne Shaheen and I — the founding co-chairs of the bipartisan Senate Diabetes Caucus — introduced legislation this week to reauthorize the Special Diabetes Program, a federal initiative that provides $160 million annually for Type 1 diabetes research and prevention. Thanks to this program and the tireless advocacy of Breakthrough T1D and its Children’s Congress Delegates, we are seeing life changing breakthroughs in the fight against this terrible disease. Some of these developments include the now widely used continuous glucose monitors, the first FDA-approved artificial pancreas, and a groundbreaking clinical trial in which 10 of the 12 participants no longer need insulin to manage their diabetes because of a stem cell-based therapy. Since the founding of the Senate Diabetes Caucus in 1997, federal funding for diabetes research has increased from $319 million to more than $2.3 billion annually. I want to thank our outstanding witnesses for today’s hearing: Ruby Whitmore of Old Town, Maine, Rachel White of North Hampton, New Hampshire, Katie Bone of Bernalillo, New Mexico, and Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Their passionate testimony highlighted both the daily realities of living with type 1 diabetes and the vital role of continued federal research through agencies like the NIDDK. Finding a cure for Type 1 diabetes remains our ultimate goal and has been one of my highest priorities since the very beginning of my Senate service. With continued advocacy, bipartisan support, and strong federal investment, I am confident that day will come.

Sen. Susan Collins

12,373 次观看 • 1 年前